Fig. 7: The miR-16 family/TFAP2A/PSG9 axis exhibits clinical effects upon LUAD. | Cell Death & Disease

Fig. 7: The miR-16 family/TFAP2A/PSG9 axis exhibits clinical effects upon LUAD.

From: TFAP2A potentiates lung adenocarcinoma metastasis by a novel miR-16 family/TFAP2A/PSG9/TGF-β signaling pathway

Fig. 7

A, B The effects of TFAP2A/PSG9 on survival rate in four independent LUAD datasets (GSE30219, GSE31210, GSE41271 and GSE50081) (A, OS rate; B, PFS rate). C, D The influence of miR-16 family/TFAP2A/PSG9 upon survival rate in TCGA-LUAD dataset (C, OS rate; D, PFS rate). E–G The influence of miR-16 family/TFAP2A/PSG9 upon TNM parameters in TCGA-LUAD dataset (E, T parameters: tumor size; F, N parameters: lymph node metastasis; G, M parameters: distant metastasis). *p < 0.05; **p < 0.01; ***p < 0.001.

Back to article page